Purpose To develop a semi-mechanistic population pharmacokinetic (PK) model to quantitate the disposition kinetics of L-histidine, a peptide-histidine transporter 1 (PHT1) substrate, in the plasma, cerebrospinal fluid and brain parenchyma of wildtype (WT) and Pht1 knockout (KO) mice.
INTRODUCTION
Proton-coupled oligopeptide transporters (POTs) are responsible for translocating various di/tripeptides and peptidomimetics across biological membranes (1, 2) . They have a significant influence on the pharmacokinetics (PK) and pharmacodynamics (PD) of their substrates (3) (4) (5) . To date, four mammalian members of the POT superfamily have been identified, including peptide transporter 1 (PEPT1) andthere is limited information available for PHT1, especially regarding the impact of PHT1 on the PK of its substrates.
PHT1 was first cloned from rat brain in 1997 (6) , where it was highly expressed in hippocampus, cerebellum and pontine nucleus, and showed high affinity to L-histidine (L-His) in Pht1-transfected Xenopus laevis oocytes (6, 7) . PHT1 was also expressed in a human blood-brain barrier cell line (8) . Our preliminary studies in rat and mice showed that PHT1 had a dominant function in brain uptake of the dipeptide substrate glycylsarcosine (9) , as well as in regulating the brain distribution of L-His (10) . PHT1 has also been found in human and rat intestinal tissue segments (11, 12) , however, its relevance in substrate absorption is unclear. Moreover, PHT1 expressed in dendritic cells is intimately involved in immunologic diseases related to TLR9 stimulation such as lupus, colitis and persistent viral infection (13) (14) (15) . Recent genome-wide association studies on systemic lupus erythematosus identified PHT1 variants as an Asian-specific locus for this disease (16) (17) (18) .
L-His was chosen as a model PHT1 substrate in this study. It is one of the essential amino acids, which can be degraded to many important metabolic products (19) . One of the most important metabolites of L-His in the brain is histamine, a neurotransmitter. It is known that histamine has difficulty passing through the barrier systems of the brain (20, 21) . The production of histamine in the central nervous system (CNS) is not only dependent upon the activity of histidine decarboxylase (HDC) (20) , but also on the availability of its precursor, LHis. Therefore, the entry of L-His in brain is correlated with histamine homeostasis (22, 23) . Brain histamine is produced in histaminergic neuronal and mast cells. There are several transporters responsible for translocating L-His into the brain cells, including L-amino acid transporters (e.g., SNATs, LATs and CATs) and PHT1 (9, 12, (24) (25) (26) (27) . However, it appears that PHT1 accounts for 50% of the uptake of L-His, as determined in mouse brain slices, while L-amino acid transporters account for 30% and other unidentified nonsaturable processes for 20% of the uptake (9, 10) .
Previous studies suggested that PHT1 plays an important role in histidine/histamine homeostasis in brain, as well as in neuropeptide regulation. Thus, understanding the uptake kinetics of PHT1 substrates could facilitate the development of drug delivery strategies for the treatment of neurological diseases related to brain histamine levels. A semi-mechanistic model could provide a useful tool in predicting the brain entry of PHT1 substrates. In order to construct the model, a nonlinear mixed-effects modeling (NONMEM) approach was performed. NONMEM is widely used in analyzing population PK data by virtue of addressing variability with different sources. In this study, a population PK model of L-His was developed in wildtype and Pht1-deficient mice. By analyzing and comparing the data collected from the two genotypes, we were able to characterize the PK properties and relative significance of PHT1 on the in vivo disposition of L-His in brain.
MATERIALS AND METHODS

Animals
Gender-and age-matched Pht1-competent (wildtype or WT) and Pht1-deficient (knockout or KO) mice, 8 to 10 weeks of age, were used in this study. The genotype, gender, age and body weight were recorded before the experiments. Pht1 KO mice were a generous gift of Dr. Noriko Toyama-Sorimachi (15) . All animals were bred on a C57BL/6 background (≥99%). The mice were housed in a temperature-controlled environment with 12 h light and dark cycles, and received a standard diet and water ad libitum (Unit of Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI). All animal studies adhered to the BPrinciples of Laboratory Animal Care^by U.S. National Institutes of Health (NIH publication #85-23, revised in 1985).
In Vivo PK and Tissue Distribution of L-His
The in vivo PK and tissue distribution data were generated previously in our laboratory (10) . In brief, a 100-μl volume of L-[ Blood samples (15-20 μl) were collected serially, via tail nicks, until mice were euthanized at 0.5, 1, 2, 5, 10, 15, 20 and 30 min after dosing. Heparinized blood samples were centrifuged immediately at 3000 g for 3 min at ambient temperature. Radioactivity of the plasma samples was then measured using a dual-channel liquid scintillation counter. CSF samples (5 μl) were obtained from the cisterna magna of mice along with brain parenchyma at specified times (e.g., 2, 5, 10, 20 or 30 min after dosing). The samples were weighed and dissolved in 330 μl of 1 M hyamine hydroxide and incubated overnight at 37°C. An intravenous bolus injection of [ 3 H]dextran-MW 70,000 (0.25 μCi/mouse) was administered just prior to harvesting the tissue samples to correct for vascular space.
Population PK Modeling of L-His in Plasma, CSF and Brain Parenchyma
The concentration-time profiles of these biological fluids and tissue were analyzed using non-linear mixed effects modeling with NONMEM v7.3 (ICON Development Solutions, MD, USA). A subroutine ADVAN6 TRANS1 and the first-order conditional estimation with interaction were used to build the compartment models throughout the modeling procedure. Model development was guided by the likelihood ratio test using objective function values, graphical goodness-of-fit, and non-parametric bootstrap analysis. A stepwise compartmental model building approach was performed in model development to characterize the disposition kinetics of L-His in the plasma, CSF and brain parenchyma. First, a PK model was developed for the plasma concentration-time data, and one-, two-, and three-compartment models were compared. Once this preliminary model was established, the plasma, CSF and brain concentration-time data were fit simultaneously to the structural model shown in Fig. 1 . This schematic model was adopted and modified based on another model (28) .
Mass-balance equations for each compartment were shown by the following equations:
For the central and peripheral compartments
For the brain parenchyma
For the CSF ) and by other pathways which were simplified as a first-order process (K 13 ). There was no PHT1 function in the KO mice. There was passive diffusion of L-His describing its exchange between the brain parenchyma and CSF compartments. Clearance between the brain and CSF compartments (Q 2 ) was assumed to be inversely proportional to the one-half power of molecular weight (MW) and estimated by Eq. 5 (28):
The distribution of L-His between the central and CSF compartments was also assumed to be a first-order process. In addition, L-His was drained from the CSF to central compartment through bulk flow (Q bulk ). Values for Q bulk and the volumes of distribution for the brain (V 3 ) and CSF (V 4 ) compartments were obtained from the literature (29) . Relationships between the micro-rate constants (e.g., K 12 and K 21, K 34 and K 43 , and K bulk ) and flows (e.g., Q 1 , Q 2 and Q bulk ) were shown by the following equations:
Inter-animal variability (IIV) of the PK parameters was assumed to follow a log-normal distribution and described by an exponential error model. Additive, proportional and mixed error models were evaluated for the residual unexplained variability. The impact of genotype, gender, age and body weight of animal on PK parameters was evaluated. IIVs and covariates were included in the model only if they were associated with a decrease in OFV by at least 3.84 (χ 2 p value ≤ 0.05). The final PK model was evaluated by nonparametric bootstrap analyses and visual predictive checks using Perlspeaks-NONMEM (PsN 4.2.0). Two hundred bootstrap samples were generated from the original data set and then fitted to the final population PK model to obtain parameter estimates. The median and 90% bootstrap confidence interval calculated from the successful bootstrap runs were compared with the final model estimates. For visual predictive checks, 1000 hypothetical datasets Fig. 1 Schematic structural model of L-histidine disposition in mice after an intravenous (iv) bolus dose. V max,PHT1 and K m,PHT1 , the maximum rate and Michaelis constant of PHT1-mediated active transport of L-histidine from plasma to brain; k 10 , k 12 , k 21 , k 13 , k 31 , k 14 , k 41 , k 34 and k 43 , the first-order micro-rate constants between the respective compartments; k bulk , the firstorder micro-rate constant of CSF bulk flow. The dashed line indicates a process existing only in wildtype mice.
were simulated using the parameter estimates of the final model. The 90% prediction intervals were calculated and checked by visual inspection to see how the intervals overlapped with the observed data.
Statistics
Experimental results were reported as mean ± SE. A twotailed unpaired Student's t-test was used to determine statistical differences between two treatment groups. A p value ≤0.05 was considered significant. As shown in Fig. 2 , brain L-His concentrations were significantly lower in Pht1 KO mice compared to WT animals at early time points (before 10 min) but less so at later ones, suggesting a difference on the distribution rate of L-His from the plasma to brain. The plasma and CSF concentration-time profiles of L-His were comparable in the two genotypes. Based on these findings, genotype differences would be considered a covariate for the uptake rate constant of L-His in brain.
Population PK Modeling of L-His in Plasma, CSF and Brain Parenchyma
A stepwise compartmental model building approach was performed to characterize the disposition kinetics of L-His in the plasma, CSF and brain parenchyma. The disposition kinetics of L-His in plasma was best described by a two-compartment model. The expanded four-compartment model, including brain parenchyma and CSF, is shown in Fig. 1 . The estimated PK parameters and bootstrap results were listed in Table I . Consistent with our previous noncompartmental analysis (10), the plasma PK parameters of L-His were comparable in WT and Pht1 KO mice. The total plasma clearance (CL) of L-His was 0.30 mL/min, and its volumes of distribution in the central (V 1 ) and peripheral (V 2 ) compartments were 4.52 mL and 5.55 mL, respectively. The distribution kinetics between plasma and CSF compartments were also similar in the two genotypes. A more rapid uptake of L-His occurred in the brain parenchyma of WT mice, as compared to Pht1 KO mice, due to its active transport by PHT1 (V max,PHT1 = 0.051 nmoL/min, K m,PHT1 = 34.94 μM), demonstrating that PHT1 plays an important role as an uptake transporter for L-His in brain. In the pilot study, L-His concentrations in brain parenchyma reached a plateau at 20 min post dose, which was consistent with the literature (30) . Therefore, we only characterized the first 30 min after dosing, which also minimized the influence of potential metabolites (i.e., nonspecificity of radiolabel) on our results. The first-order rate constant directing L-His from the brain parenchyma to central compartment (K 31 ) was fixed as zero in the final model. The impact of mouse genotype, gender, age and body weight on the PK parameters was evaluated. Only genotype was Fig. 3 Basic goodness-of-fit plots for the population pharmacokinetic parameters of L-histidine in plasma, CSF and brain. Geo. mean is the geometric mean, PRED is the population prediction, IPRED is the individual prediction, and CWRES is the conditional weighted residual.
incorporated as a covariate in the final model. An additive error model was used to describe the residual unexplained variability.
Final Model Validation
Basic goodness-of-fit plots for the final PK model were displayed in Fig. 3 . Individual predictions showed a good correlation with observed concentrations in all of the plasma, brain parenchyma and CSF compartments. Conditional weighted residuals randomly distributed along the zeroordinate line with no obvious deviations. As shown in the visual predicted check plots (Fig. 4) , observed concentrations in the plasma and CSF compartments were in good agreement with the prediction intervals of 1000 simulations based on parameter estimates from the final model. However, there was some deviation in the median of predicted values for brain parenchyma in which the observed data were overpredicted at 20 min in wildtype mice and underpredicted at 10 and 30 min in Pht1 null mice. Notwithstanding this finding, nonparametric bootstrap analyses (Table I) showed that all parameter estimates were close to the median and were inside the 90% confidence intervals of the bootstrap estimates.
DISCUSSION
There is emerging evidence showing that PHT1 plays an important role in the brain as an uptake transporter. In particular, the protein expression of PHT1 in brain increased with age in both mice and rats, with its functional activity dominating the uptake of glycylsarcosine in adult rodent brain slices (9) . Moreover, our previous findings have demonstrated that PHT1 was the major transporter in regulating the in vitro distribution of L-His in brain, where it accounted for 50% of the total uptake of L-His in hypothalamus slices. In contrast, the L-amino acid transporters accounted for only 30% of the uptake and other nonsaturable pathways for the remaining 20% (10) . The brain distribution of L-His in vivo was also significantly reduced in Pht1-deficient mice, as compared to wildtype mice. In the present study, the PK properties of PHT1 in vivo were characterized for the first time and several new findings were revealed. Specifically, a four-compartment PK model was successfully developed to define the distribution kinetics of the PHT1 substrate L-His from the central compartment to the brain. By comparing wildtype with Pht1 KO mice, we could quantify the PHT1-mediated active transport of L-His from the plasma to brain in vivo with a single Michaelis-Menten term (V max,PHT1 = 0.051 nmoL/min, K m,PHT1 = 34.94 μM). Moreover, the similar disposition kinetics of L-His in plasma and CSF between the two genotypes suggested the absence of PHT1 at the blood-CSF and the brain parenchyma-CSF interfaces.
The estimated K m,PHT1 value of L-His (34.94 μM) in mice from the final model was close to that reported previously from an in vitro experiment of L-His (K m = 17 μM) in rat Pht1-expressing Xenopus oocytes (6) . This finding, and their close homology (97% amino acid identity), further adds to the plausibility of the current model regarding the PHT1-mediated plasma-to-brain uptake of L-His. This result from our study also demonstrated that the PHT1 in mouse is a high affinity transporter similar to that in rat (6) . PHT1 is widely distributed throughout rat whole brain (6) and expressed in a human blood-brain barrier cell line (8) . Therefore, it is possible that PHT1 may contribute to the translocation of L-His from blood to brain parenchyma, as well as from brain extracellular fluid to brain cells. In order to differentiate these two pathways, further investigation is needed, perhaps, by using a microdialysis study design.
As shown in Eq. 3, the uptake of L-His in brain was described by a combination of PHT1-mediated uptake and nonsaturable processes. These processes may reflect passive uptake and/or L-amino acid transporters at the blood-brain barrier, which have Km values in the mM range for SNATs (31) and CATs (32) and 135 μM in RBE4 cells representative of LATs (33) , and are assumed not to be saturable in our model. Under linear-conditions (i.e., plasma concentrations << K m,PHT1 ), the rate constant for PHT1-mediated uptake of L-His could be roughly estimated as V max /(V 1 *K m ) = 3.2 × 10 −4 1/min. As reported in Table I , the rate constant representing the uptake mediated by other pathways (K 13 ) was equal to 16 × 10
1/min. Using these numbers, the total first-order plasmato-brain uptake of L-His would approximately equal 1.9 × 10 −3 1/min in wildtype mice, which was close to the literature values of 0.5 -13.4 × 10 −3 1/min, as reported in rat (22, 34) . Thus, the contribution of PHT1-mediated uptake of L-His in brain was calculated at about 20% in vivo, which was smaller than the 50% value determined previously in vitro from mouse brain slices (10) . Although speculative, this difference may reflect the fact that in vitro brain slice results are obtained from a stagnant system, whereas in vivo brain results are dynamic and include the temporal aspects of blood flow, membrane residence times and other physiological factors. It should also be appreciated that the % RSE for V max was high and, if taken into account, the percent contribution of PHT1 could be as high as 30% for the uptake of L-His in brain. Expression profiling has also revealed the gene expression of Slc7 and Slc38 transporters in mouse choroid plexus (35) . However, their protein expression levels and functional significance have not been determined. Notwithstanding this uncertainty, the apical location of System N amino acid transporters (and perhaps others) could account for the much greater efflux of L-His from the CSF to central compartment than the reverse (i.e., K 41 ⋅V 4 > > K 14 ⋅V 1 ).
A semi-mechanistic model would be more valuable if we were able to extrapolate these findings in mice to humans. Thus, it would be important to determine the protein expression levels of PHT1 and related transporters in human so that the brain distribution of L-His or future PHT1-substrate drugs could be simulated. Moreover, considering the number of PHT1 variants and their association with lupus systemic erythematosus (16) (17) (18) , further investigation of PHT1 localization, structure-function and regulation in the brain is warranted.
In conclusion, a semi-mechanistic population pharmacokinetic model was developed that successfully characterized the disposition of L-His, a model PHT1 substrate, in mouse plasma, CSF and brain parenchyma. By modeling the data collected from Pht1-competent and Pht1-deficient mice simultaneously, we were able to describe for the first time the quantitative contribution of PHT1 in the plasma-to-brain uptake of L-His under in vivo conditions. This model may prove a useful tool in predicting the brain distribution of L-His in humans, and PHT1 as a possible target in brain for the delivery of peptide/mimetic therapeutics.
